Clinically driven TLR rates were significantly lower with Supraflex Cruz, supporting its superior performance in reducing the need for repeat interventions. Stent thrombosis rates with Supraflex Cruz were impressively low, even in this high-risk population. This trial marks the first major study to include only HBR patients in accordance with the ARC HBR guidelines, making it a pioneering study for managing patients who are at both high bleeding and ischemic risk.

The trial results demonstrate the non-inferiority of the Supraflex Cruz stent compared to the Ultimaster Tansei stent in terms of net adverse clinical events (NACE) at 12 months, with event rates of 15.4% and 17.1%, respectively (P=0.02 for noninferiority). Notably, the Supraflex Cruz stent showed a significant reduction in clinically driven target lesion revascularization (TLR) rates and very low rates of stent thrombosis, despite the fact that the enrolled patients were at substantial risk for bleeding and ischemic events.

Aspirin hypersensitivity represents a significant clinical challenge in patients with CAD who require aspirin as part of an antithrombotic treatment. The percentage of patients reporting aspirin hypersensitivity is in fact high, although the real prevalence is low in general population, making it crucial to identify those patients who really are hypersensitive. The mechanisms underlying aspirin hypersensitivity, moreover, are not fully understood, and further studies are needed to better understand the pathophysiology beneath this condition. Despite these challenges, and depending on the clinical setting, multiple strategies are available to allow aspirin administration in patients with CAD and reporting drug hypersensitivity, and suspicion of this condition should not automatically deter the use of aspirin. The low-dose ASA challenge and desensitization are in fact safe and effective strategies to overcome this condition, although still underused in clinical practice. For those few patients who cannot (or fail to) undergo ASA desensitization, further approaches may be also considered, including the use of alternative antiplatelet agents or antithrombotic regimens.

This study identifies CCDC8 as a key mediator of cardiomyocyte apoptosis via the TNF signaling pathway in myocardial I/R injury. These findings suggest that targeting CCDC8 could be a potential therapeutic strategy for mitigating cardiac dysfunction in myocardial I/R injury.

AST modulates inflammatory signaling pathways such as NF-kB and downregulates the expression of inflammatory cytokines. Although there are only a few clinical reports related to the protective effect of AST against inflammatory diseases, AST should be further characterized for its properties as a potential therapeutic strategy in combating inflammatory diseases.

The ChampioNIR Drug-Eluting Peripheral Stent System poses a transformational technology designed to improve patient outcomes and procedural success. In a first of its kind hybrid mechanical design, radial support is provided by the metallic component of the stent, whereas longitudinal structure is provided by a bioresorbable polymeric mesh providing unsurpassed flexibility and long-term durability in even the most challenging anatomies. Furthermore, a unique drug-elution paradigm releases drug from the entire cylindrical area of the stent, drastically reducing diffusion distances and allowing, for the first time, therapeutic dosing of a large peripheral vessel with a 'limus' drug for an extended period of time.

The European Society of Cardiology (ESC) has issued updated guidelines on the management of chronic coronary syndrome, with new recommendations covering diagnosis, timing of revascularisation, and a stronger emphasis on the use of intracoronary imaging to guide revascularisation procedures.

The findings demonstrate that oral administration of Provinols™ has the potential to reduce in-stent neointimal growth and lipid deposition, likely due to its anti-inflammatory properties in iliac arteries from hypercholesterolemic rabbits. Additionally, these findings provide an evidence-based rationale for the potential therapeutic benefits of plant-derived polyphenols in the prevention of restenosis associated with stent placement.

Combining alkaline heat treatment, dopamine self-polymerization, and surface in-situ grafting technologies, PEG-Hep-SeCA and GOCS-CO functional molecules were successfully introduced on the surface of magnesium alloy. The bioactive coatings with different contents of CO-releasing molecules were fabricated on the surface, which can catalyze the simultaneous release of CO and NO. The coating can enhance the hydrophilicity and anticorrosion properties of magnesium alloy and has a certain selective

Over the last decades, the role of CCTA in managing CAD has become prominent, with modern scanners delivering high-quality images, even for challenging cases, and landmark trials establishing its first-line role.

Xinhua News Agency, Tianjin, Oct. 5 (Xinhua) -- In the face of three consecutive years of losses, sales fluctuations in the predicament, is it difficult to retreat or rise to the challenge? Is it to change the track or stick to the original intention? This is a story of innovation and breakthrough in the face of adversity, and also a sample of an enterprise's upward climb. Sinomed, an interventional medical device company founded by returnees, how to get out of the road of independent innovation in more than ten years of perseverance? How to grow up in the midst of difficulties?

We found that neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR), and monocyte-to-HDL-C ratio (MHR) levels are associated with the severity of coronary artery disease. We think that adding these easily and quickly measurable parameters to routine laboratory results may support the clinician in evaluating the complexity of coronary artery disease and guiding treatment decisions in NSTEMI patients.

In certain complex percutaneous coronary intervention (PCI) cases where there may be a discrepancy in the diameter of the treated vessel, using a stent that has the ability to adapt to the anatomy of the artery can be advantageous.

Among patients undergoing PCI, those with HBR were at increased long-term risk for both bleeding and ischaemic events, with a greater risk of mortality compared to non-HBR patients.

Excessive stent strut protrusion in the distal left main (LM) from either the left anterior descending (LAD) or circumflex (Cx) artery following inadequate ostial stenting may complicate any later procedure involving the left coronary artery. In such case scenarios, intravascular ultrasound (IVUS) guidance provides accurate assessment of the ostial stent position and may facilitate subsequent management strategies and treatment.

De-escalation to ticagrelor monotherapy does not increase ischaemic risk and reduces the risk of major bleeding when compared to 12 months of dual antiplatelet therapy (DAPT) following percutaneous coronary intervention (PCI), particularly among patients with acute coronary syndromes (ACS).

Among strategies of DAPT modulation for patients with ACS undergoing PCI, we found no difference in the risk for death between short DAPT and de-escalation. De-escalation was associated with a reduced risk for NACE, while short DAPT was associated with a reduced risk for major bleeding. In the absence of direct randomized comparisons, these data may inform clinicians on the relative merits of 2 contemporary DAPT strategies and allow personalized treatment decisions on the basis of treatment objectives and the balance between the risks for thrombosis and bleeding.

Our study successfully developed a double-layer coated DAC stent that exhibited favorable biocompatibility and preserved the normal physiological functions of VECs and contractile phenotype of VSMCs in vitro. In vivo experiments conducted on rabbits demonstrated that the DAC stents effectively recruited Sca-1+ cells and promoted their differentiation into both VECs and contractile VSMCs. This process facilitated vascular repair, attenuated ISR, and mitigated inflammatory reactions

Efficient delivery of drugs within the brief procedural window while minimizing drug loss during maneuvering to the target site remains a challenge. Herein, we developed a pressure-responsive and pH-triggered, paclitaxel (PTX) coated DEB catheter for rapid and high-dose delivery of paclitaxel to the lesion sites, overcoming the limitations of drug dispersion and inefficiencies associated with conventional DEBs. Using the charge reversion of albumin around its isoelectric point, paclitaxel-loaded human serum albumin nanoparticles (PTX-HSA-NPs) and heparin were coated using a layer-by-layer deposition method at pH 4.0. Upon exposure to physiological pH (i.e., 7.4), the coating is rapidly released from the balloon surface.

Single-layered endothelial coverage begins in the days after newer-generation DES placement, and BP-DES potentially exhibit faster strut coverage with smooth muscle cell infiltration than DP-DES in humans. Nevertheless, vessel healing remains suboptimal in both stents at 30 days.